Momenta Pharmaceuticals Given Consensus Recommendation of “Buy” by Brokerages (NASDAQ:MNTA)
Momenta Pharmaceuticals (NASDAQ:MNTA) has earned an average recommendation of “Buy” from the eight analysts that are covering the stock, StockRatingsNetwork.com reports. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $18.83.
Several analysts have recently commented on the stock. Analysts at Maxim Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, June 5th. They set a “buy” rating and a $17.00 price target on the stock. Separately, analysts at Goldman Sachs initiated coverage on shares of Momenta Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $19.00 price target on the stock.
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at 12.99 on Tuesday. Momenta Pharmaceuticals has a 1-year low of $9.85 and a 1-year high of $19.90. The stock’s 50-day moving average is $11.98 and its 200-day moving average is $15.0. The company’s market cap is $668.3 million.
Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.55) by $0.02. The company had revenue of $10.79 million for the quarter, compared to the consensus estimate of $8.41 million. During the same quarter in the prior year, the company posted ($0.48) earnings per share. The company’s quarterly revenue was up 42.1% on a year-over-year basis. Analysts expect that Momenta Pharmaceuticals will post $-0.48 EPS for the current fiscal year.
Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.